Use of carprofen for the treatment of pain and inflammation in dogs.
Most studies of nonsteroidal anti-inflammatory drugs (NSAID) do not demonstrate appreciable differences in efficacy. As awareness of the adverse effects associated with NSAID use increases, safety is becoming the primary concern among physicians when selecting NSAID for use by their human patients. However, veterinarians may be less aware of the safety concerns associated with NSAID use. A wide range of NSAID is used to treat human beings with osteoarthrits; however, it is imperative to remember that dogs are especially sensitive to these drugs, and reports of serious, and occasionally fatal, complications are numerous. Carprofen is a propionic acid-derived NSAID that has anti-inflammatory, analgesic, and antipyretic activity. In animals, carprofen is as potent as indomethacina and more potent than aspirin or phenlbutazone, but carprofen appears to be safer than most other NSAID.
Fox
S M
SM
Companion Animal Technical Services Division, Pfizer Animal Health, Exton, PA 19341, USA.
Johnston
S A
SA
D000082:Acetaminophen / Q000009:adverse effects / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D002227:Carbazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003002:Clonixin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D007052:Ibuprofen / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use; D007660:Ketoprofen / Q000009:adverse effects / Q000627:therapeutic use; D008469:Meclofenamic Acid / Q000009:adverse effects / Q000627:therapeutic use; D000077239:Meloxicam; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use; D010003:Osteoarthritis / Q000188:drug therapy / Q000662:veterinary*; D010146:Pain / Q000188:drug therapy / Q000662:veterinary*; D010653:Phenylbutazone / Q000009:adverse effects / Q000627:therapeutic use; D010894:Piroxicam / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013843:Thiazines / Q000494:pharmacology / Q000627:therapeutic use; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use
D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002227:Carbazoles; D016861:Cyclooxygenase Inhibitors; D013843:Thiazines; D013844:Thiazoles; D010894:Piroxicam; D000082:Acetaminophen; D008469:Meclofenamic Acid; D009288:Naproxen; C014558:flunixin meglumine; D007660:Ketoprofen; C007005:carprofen; D010653:Phenylbutazone; D001241:Aspirin; D003002:Clonixin; D000077239:Meloxicam; D007052:Ibuprofen; D007213:Indomethacin